KRT18 and breast cancer: In serum, the results (Supplementary Figure S5B) indicated that reports used M30 antibody to detect the expression of CK18 predicted a poor outcome of breast cancer (HR = 1.26, 95%CI: 1.13–1.41, P<0.001), which is consistent with the subgroup analysis based on specimen sources.